Novasecta’s Managing Partner, John Rountree, was asked by Bloomberg to comment on GSK pulling their bid for Pfizer Consumer-Health Unit. John commented “this tells you about big pharma’s attitude toward consumer health — the brutal reality is that consumer health is not as profitable as the pharma business. There is something inherently unattractive about consumer health from a profitability point of view.” Elaborating John added “There is a tremendous chance of something big, while consumer health offers the potential for cost savings, it doesn’t offer the same upside.
To view the full Bloomberg article, click here.
Insights
GSK withdraws from Consumer-Health bid (Bloomberg)
Novasecta’s Managing Partner, John Rountree, was asked by Bloomberg to comment on GSK pulling their bid for Pfizer Consumer-Health Unit. John commented “this tells you about big pharma’s attitude toward consumer health — the brutal reality is that consumer health is not as profitable as the pharma business. There is something inherently unattractive about consumer health from a profitability point of view.” Elaborating John added “There is a tremendous chance of something big, while consumer health offers the potential for cost savings, it doesn’t offer the same upside.
To view the full Bloomberg article, click here.
Related
Insights
Five Imperatives For Strategic And Operational Excellence
DiscoverTransform Value And Access Into A Global Leadership Function
DiscoverCreating an Effective Pharma R&D Mindset: Lessons from Pioneers
Discover